3 results
The Primary Objective of the study is to dettermine the relative efficacy of AZD2171 [RECENTIN] (both monotherapy or in combination with oral lomustine) compared to oral lomustine alone by assessment of progression free survival (PFS) as assessed by…
Primary To test the hypothesis that at least 1 dose of LY2951742 (120 mg or 240 mg/month) is superior to placebo in the prevention of migraine headache in patients with chronic migraineKey Secondary Objectives If LY2951742 (120 or 240 mg/month) is…
The primary objective is to compare the objective response rate (ORR) per Response Assessment in Neuro Oncology (RANO) criteria assessed by independent review committee (IRC) of DAY101 monotherapy versus standard of care (SoC) chemotherapy in…